By Alain J. Gilbert, Co-Chair, Bionest Partners Rare and orphan diseases have grown dramatically as a focus of drug development since the passage of the Orphan Drug Act and the institution of other regulatory and financial incentives in both the United States and Europe aimed at spurring development for such conditions. Franҫois Beaubien, Ph.D....